NICE Approves Ruxolitinib Cream for Treating Vi...

By HEOR Staff Writer

February 25, 2026

NICE Backs Ruxolitinib Cream Vitiligo Treatment Ruxolitinib cream vitiligo therapy has received a major endorsement from the National Institute for Health and Care Excellence (NICE), w...
Enhancing Safety and Performance: The Role of EU Medical Device Panels
Genotype ECG Prediction
National HealthTech Access: Transforming NHS Adoption and Equity
NICE Endorses Talazoparib Enzalutamide for Prostate Cancer Treatment
Trump Economic Revival: Key Policies and Impacts from Davos 2026
EU Medicine Authorizations 2025: A Milestone for Innovation and Accessibility
Obesity Medication Guidelines: Evidence-Based Approaches to Effective Treatment
Johnson & Johnson’s Medicine Access Agreement: Paving the Way for ...
Bausch Health’s Strategic Growth in Latin American Pharmaceuticals Thro...
Johnson & Johnson’s EMA Application for Teclistamab Daratumumab Th...
Accelerating Tec-Dara Multiple Myeloma Therapy Review: A Game Changer for Pat...
AKEEGA BRCA2 Approval: Landmark FDA Decision for Precision Therapy in Aggress...